Bispecific antibodies in cancer therapy

Bispecific antibodies in cancer therapy: Target selection and ...

The FDA first issued draft guidance for Bispecific Antibody Development Programs on April 19, 2019, followed by a final version on May 24, 2021.

The present and future of bispecific antibodies for cancer therapy

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic applications that cannot be achieved using conventional ...

Bispecific antibodies: advancing precision oncology: Trends in Cancer

Highlights. Bispecific antibodies (bsAbs) offer a novel approach to anticancer therapy by targeting different antigens via a range of mechanisms ...

Bispecifics antibodies: The next big thing in lymphoma treatment

These bispecific antibodies treat cancer by engaging the tumor-specific antigen CD20 and the CD3 antigen on T cells. "Bispecifics allows us to ...

Bispecific Antibody Immunotherapy - Cancer Support Community

Get a simple explanation of how bispecific antibody drugs work to help the immune system fight cancer cells and learn about possible side effects.

Current landscape and future directions of bispecific antibodies in ...

Bispecific T cell engagers (BiTEs) have revolutionized success in hematological malignancies treatment and revitalized the field of solid tumor immunotherapy ...

Bispecific antibodies: advancing precision oncology - ScienceDirect

BsAbs have shown high clinical efficacy in R/R hematological malignancies, with rapid developments across this field. Multiple clinical investigations are ...

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response ...

Among all the antibody-centered cancer therapy, T-cell engaging bispecific antibodies (T-biAbs) have a promising role in future cancer ...

Bispecific Antibodies: An Area of Research and Clinical Applications

Investigators found that the BsAb spurred anti-tumor activity in several ways, namely by stopping cancer cell growth and disrupting the cell ...

Efficacy and safety of bispecific antibodies vs. immune checkpoint ...

In recent years, bispecific antibodies (BSABs) have emerged as a novel strategy in tumor immunotherapy. BSABs combine two distinct antigen ...

Bispecific antibodies in oncology - Nature

Approved bispecific antibodies. In 2014, blinatumomab (Blincyto; Amgen) became the first bsAb to gain FDA approval. This CD19×CD3 BiTE is ...

'Switchable' bispecific antibodies pave way for safer cancer treatment

Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that ...

Bispecific Therapy treatments - Florida Cancer Specialists

Talquetamab (TALVEY™) is proven to be an effective bispecific antibody treatment for relapsed/refractory multiple myeloma (RRMM) in patients who have received ...

Bispecific Antibodies - BC Cancer

Bispecific antibodies engaging T-cells have emerged as an innovative form of immunotherapy, seamlessly combining two antigen-recognizing elements into a single ...

How Can Bispecific Antibodies Treat Blood Cancer?

Bispecific antibodies are being researched to treat blood cancers like leukemia, lymphoma and multiple myeloma. New therapies are available to ...

Frontiers | Bispecific antibodies revolutionizing breast cancer treatment

Bispecific antibodies (BsAbs) have emerged as a promising approach to treating BCa, offering unique capabilities for targeted therapy and immunomodulation (2).

Bispecific Therapies | International Myeloma Foundation

Bispecific antibodies (also known as bispecifics, or BsAbs) are an immunotherapy (immune cell therapy) showing promising clinical trial results.

Targeted Antibodies Immunotherapy - CRI - Cancer Research Institute

The first bispecific antibody—a BiTE called blinatumomab (Blincyto®)—was approved by the FDA in 2014 for subsets of patients with leukemia. Other bispecific ...

Bispecific Antibodies: What They Are & How They Treat Cancer

Bispecific antibodies are a form of immunotherapy that may allow the body to target and destroy cancer cells. Learn about this treatment and ...

Bispecific antibody - AstraZeneca

Bispecific antibodies are a promising approach in Immuno-Oncology. By using antibody engineering techniques, we can combine the potential benefits of two ...